Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999385 | Urologic Oncology: Seminars and Original Investigations | 2016 | 7 Pages |
Abstract
ClearCode34, after considering distinct patterns of comorbidities in each molecular subtype, remains a strong prognostic tool in patients with ccRCC. Obesity and diabetes mellitus emerged as factors that may influence ccRCC phenotypes and further studies investigating the effect of these metabolic conditions functionally onto tumor biology are warranted. Additionally, use of angiotensin system inhibitors could be studied in the context of ccRCC molecular classification in future studies to better understand its effect on ccRCC outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Scott M. M.D., Samira A. Ph.D., Eric Ph.D., William J. M.S., Dung-Tsa Ph.D., Jasreman M.D., Eric M.D., Wade M.D., Philippe E. M.D., Julio M.D., W. Kimryn M.D., Ph.D., Mayer M.D., Ph.D.,